Novelion Therapeutics’ European subsidiary files a Marketing Authorization Application seeking approval for Orphan Drug-tagged metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy and in a subgroup of patients with partial lipodystrophy . If approved, the product will be marketed under the brand name MYALEPTA.